Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth - Peter, B; Winter, G E; Blatt, K; Bennett, K L; Stefanzl, G; Rix, U; Eisenwort, G; Hadzijusufovic, E; Gridling, M; Dutreix, C; Hoermann, G; Schwaab, J; et al. (Leukemia, 2016)
Keywords: 13/31; 13/89; 631/67/1990/283; 82/16; Adult; Aged; Basophils - drug effects; Basophils - physiology; Cancer Research; Cell interaction; Cell Line, Tumor; Cell Survival - drug effects; Cellular proteins; Critical Care Medicine; Dephosphorylation; Drug therapy; Enzyme inhibitors; Female; Genetic aspects; Health aspects; Hematology; Histamine; Histamine Release - drug effects; Humans; In vivo methods and tests; Intensive; Internal Medicine; Kinases; Leukemia; Leukocytes (basophilic); Lysates; Male; Mast cell disease; Mast cells; Mast Cells - drug effects; Mast Cells - physiology; Mastocytosis; Mastocytosis - drug therapy; Mastocytosis - pathology; Medicine; Medicine & Public Health; Metabolites; Methods; Middle Aged; Molecular targeted therapy; Oncology; original-article; Patient outcomes; Patients; Protein kinase C; Protein Kinase Inhibitors - pharmacology; Proteomics; Proto-Oncogene Proteins c-kit - metabolism; Signs and symptoms; Staurosporine - analogs & derivatives; Staurosporine - pharmacology; Syk protein; Austria